Biolegend, 564404, Recombinant Human TMIGD2 (CD28H)-Fc Chimera (carrier-free), 25μg

CD28H, initially called TMIGD2 (transmembrane and immunoglobulin domain containing 2), is a single transmembrane protein with one immunoglobulin variable-like (IgV) domain, and a long intracellular domain. CD28H shares approximately 10% homology with CD28, CTLA, ICOS and PD-1. CD28H is conserved in zebra fish, cow, guinea pig, and chimpanzee but the coding gene is not present in mouse and rat. The ligands for CD28H are B7-H7 and CD28H. B7-H7 orthologues do not exist in mice and rats. B7-H7 is expressed in multiple human cancers including osteosarcomas, oral, bladder, intrahepatic, and colorectal cancers. Interaction of APC or B7-H7 positive tumor cells with primary NK and naïve T cells expressing CD28H induces activation of naïve NK and T cells. CD28H/B7- H7 interaction promotes T cell proliferation and cytokine secretion including IFN-γ, IL-5, IL-10, and IL-17. The interaction of B7-H7 and CD28H also promotes NK cell degranulation. After activation of T and NK cell, expression of CD28H progressively declines. Interaction between B7-H7 and KIR3DL3 may produce antagonistic effects compared to effects elicited from CD28H/B7-H7 interaction. When activated KIR3DL3 positive T and NK cells interact with APC or B7-H7 positive cancer cells, T cell proliferation, cytokine production, and NK cell activation are inhibited.
25μg
Source: Recombinant human TMIGD2 (CD28H)-Fc Chimera, amino acid sequence containing Leu23-Gly150 (Accession No. Q96BF3) was expressed in 293E cells. The carboxy-terminus contains SR-IEGRMD-hIgG1 (Pro100-Lys330)-Fc tag.
Molecular Mass: The 367 amino acid recombinant protein has a predicted molecular mass of approximately 40.8 kD. The DTT-reduced and non-reduced proteins migrate at approximately 60 -70 kD and 100 -110 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Leu.
Purity: > 95%, as determined by Coomassie stained SDS-PAGE.
Formulation: 0.22 µm filtered protein solution is in PBS, pH 7.2
Endotoxin Level: Less than 0.1 EU per µg cytokine as determined by the LAL method.
Concentration: 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity: When recombinant human TIMIGD2 (CD28H)-Fc is immobilized at 2 µg/mL, recombinant human B7-H7 binds in a dose-dependent manner. HRP anti-His tag (Cat. No. 652503) was used to detect the binding. The ED50 for this effect is 1.5 – 9 µg/mL.
Application: Bioassay
Application Notes: BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Structure: Dimer
Distribution: Naïve T cells, innate lymphoid cells, NK cells, and plasmacytoid dendritic cells, moderate levels on memory T cells
Function: Stimulates naïve T cells proliferation and cytokine production, activates NK cells and NK cell degranulation
Interaction: Monocytes, macrophages, and activated dendritic cells, antigen presenting cells, tumor cells
Ligand/Receptor: B7-H7 (HHLA2)
Bioactivity: Measured by its ability to bind recombinant human B7-H7
Cell Type: Dendritic cells, NK cells, T cells
Biology Area: Adaptive Immunity, Cancer Biomarkers, Immuno-Oncology, Immunology, Inhibitory Molecules, Innate Immunity
Molecular Family: Adhesion Molecules, CD Molecules, Fc Receptors, Immune Checkpoint Receptors, Soluble Receptors
Antigen References: Zhao R, et al. 2013. Proc Natl Acad Sci U S A. 10:9879-84. Zhou Y, et al. 2013. Nat Commun. 44:2043. Crespo J, et al. 2017. Oncoimmunology. 6:e1362529. Rieder SA, et al. 2021. Cell Mol Immunol. 18:1503-1511. Janakiram M, et al. 2015. Clin Cancer Res. 21:2359-66. Ying H, et al. 2022. eBioMedicine. 79:103987. Luu K, Schwarz H and Lundgvist A. 2021. Front Immunol. 12:682627.
Gene ID: 126259
UniProt: View information about CD28H on UniProt.org
Regulatory Status: RUO
Other Names: IGPR-1, TMIGD2, CD28 Homolog, IGPR1
Q: Why choose BioLegend recombinant proteins?
A: • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.
Q: How does the activity of your recombinant proteins compare to competitors?
A: We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
Q: What is the specific activity or ED50 of my recombinant protein?
A: The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
Q: Have your recombinants been tested for stability?
A: Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
Q: Does specific activity of a recombinant protein vary between lots?
A: Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
Q: How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
A: Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)